Table 1 Patient baseline characteristics and disposition
Characteristic | n = 35 |
|---|---|
Age, median (range) years | 60 (46–75) |
Sex | |
Men | 17 (49%) |
Women | 18 (51%) |
Disease stage at diagnosisa | |
Stage I | 19 (54%) |
Stage II | 6 (17%) |
Stage III | 4 (11%) |
Unknown | 6 (17%) |
ECOG PS | |
0 | 10 (29%) |
1 | 25 (71%) |
Myeloma light chain | |
Kappa light chain | 24 (69%) |
Lambda light chain | 11 (31%) |
Myeloma immunoglobulin | |
IgA | 8 (23%) |
IgG | 22 (63%) |
IgM | 1 (3%) |
Other | 4 (11%) |
Genetics, n (%)b | |
del13 | 6 (17%) |
del17p13 | 6 (17%) |
t(11:14) | 2 (6%) |
t(4:14) | 3 (9%) |
t(14:16) | 1 (3%) |
1q21 | 3 (9%) |
Other | 14 (40%) |
Missing | 11 (31%) |
Prior therapies | |
1 line | 1 (3%) |
2 lines | 2 (6%) |
3 lines | 7 (20%) |
4 lines | 5 (14%) |
5 lines | 6 (17%) |
6 lines | 3 (9%) |
7 lines | 2 (6%) |
8 lines | 3 (9%) |
9 lines | 2 (6%) |
10 lines | 2 (6%) |
>10 lines | 2 (6%) |
Proteasome inhibitors | |
Received | 35 (100%) |
Refractory | 34 (97%) |
Immunomodulatory drugs | |
Received | 35 (100%) |
Refractory | 33 (94%) |
Pomalidomide | |
Received | 22 (63%) |
Refractory | 22 (63%) |
Daratumumab | |
Received | 14 (40%) |
Refractoryc | 14 (40%) |
Carfilzomib | |
Received | 29 (83%) |
Refractory | 27 (77%) |
Patient disposition | |
Completed study | 22 (63%) |
Died | 4 (11%) |
Ongoing on study | 8 (23%) |
On treatment | 1 (3%) |
In follow-up | 7 (20%) |
Withdrawn from study | 1 (3%) |
Withdrew consent | 1 (3%) |
Lost to follow-up | 0 |
Discontinued treatment | 34 (97%) |
Disease progression | 18 (51%) |
Completion of treatment | 9 (26%) |
Adverse event | 4 (11%) |
Investigator discretion | 1 (3%) |
Patient decision | 2 (6%) |
